Korro Bio's fundamental outlook is dominated by persistent operating losses, with operating income reaching -$20.1M in 2026Q2 against R&D spend of $13.6M, and free cash flow turning to -$33.1M in the same quarter, roughly double the prior quarter's outflow.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.98+22.3% vs -$1.26 | — vs $187,500 |
Q3 2026 Aug 6, 2026 | -$1.07+20.1% vs -$1.34 | $2M+600.0% vs $214,286 |
Q2 2026 May 7, 2026 | -$1.69-5.6% vs -$1.60 | — vs $761,167 |
Q2 2026 Mar 12, 2026 | -$5.32-175.6% vs -$1.93 | $1M+85.7% vs $700,000 |
Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) major shareholder Lynx1 Capital Management Lp bought 25,124 shares of the stock in a transaction on Monday, October 26th. The shares were purchased at an average price of $11.75 per share, with a total value of $295,207.00. Following the acquisition, the insider owned 1,624,789 shares in the
Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) major shareholder Lynx1 Capital Management Lp acquired 52,175 shares of Korro Bio stock in a transaction that occurred on Thursday, October 22nd. The shares were purchased at an average price of $10.72 per share, with a total value of $559,316.00. Following the transaction, the insider owned 1,597,155
Korro Bio, Inc. (KRRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-fold KRRO-111 reduced pathogenic hepatic Z-AAT by up to 95%, highlighting its potential to reduce toxic protein accumulation in the liver Best-in-class preclinical profile supports KRRO-111's potential to address both liver and lung manifestations of AATD; regulatory submission expected in the first half of 2027 CAMBRIDGE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced preclinical results for its pipeline program KRRO-111 for the potential treatment of alpha-1 antitrypsin deficiency (AATD) delivered subcutaneously.
Benchmark KRRO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Korro Bio, Inc. (KRRO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.75 | $146.81M | -2.48 | 181.46% | -8214.47% | -117.05% | — | |
| $26.41 | $2.72B | -25.82 | 120.01% | -73.04% | -9.69% | — | |
| $2.57 | $394.4M | -4.15 | 25.39% | -157.32% | -196.63% | — | |
| $50.07 | $4.83B | -10.62 | -89.97% | -1812.07% | -25.59% | — | |
| $11.35 | $1.27B | -3.73 | 16.92% | -805.75% | -64.73% | — | |
| $4.65 | $839.87M | -4.39 | 55.28% | -4613.11% | -188.27% | — |
Korro Bio, Inc. (KRRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Korro Bio, Inc. (KRRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 11, 2026·SEC
May 19, 2026·SEC
Get notified when KRRO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Korro Bio, Inc. (KRRO) stock FAQ — growth, dividends, profitability & financials explained
Korro Bio, Inc. (KRRO) reported $1.3M in revenue over the trailing twelve months. Revenue was $6.4M in fiscal year 2025.
Korro Bio, Inc. (KRRO) revenue fell by 82.5% over the trailing twelve months, compared with the twelve months before.
No. Korro Bio, Inc. (KRRO) reported a net loss of $106.1M over the trailing twelve months.
Korro Bio, Inc. (KRRO) had a return on equity (ROE) of -117.1% over the trailing twelve months. A negative ROE means the company lost money over the period.
Korro Bio, Inc. (KRRO) had negative free cash flow of $63.9M over the trailing twelve months.
